EUROMAX is a randomized , international , prospective , open-label ambulance trial comparing bivalirudin with standard-of-care anticoagulation with or without glycoprotein IIb/IIIa inhibitors in 2200 patients with STEMI and intended for primary percutaneous coronary intervention ( PCI ) , presenting either via ambulance or to centers where PCI is not performed .